vs

Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

Caledonia Mining Corp Plc is the larger business by last-quarter revenue ($46.9M vs $28.8M, roughly 1.6× X4 Pharmaceuticals, Inc). Caledonia Mining Corp Plc runs the higher net margin — 7.0% vs 1.0%, a 6.0% gap on every dollar of revenue.

Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

CMCL vs XFOR — Head-to-Head

Bigger by revenue
CMCL
CMCL
1.6× larger
CMCL
$46.9M
$28.8M
XFOR
Higher net margin
CMCL
CMCL
6.0% more per $
CMCL
7.0%
1.0%
XFOR

Income Statement — Q3 FY2024 vs Q1 FY2025

Metric
CMCL
CMCL
XFOR
XFOR
Revenue
$46.9M
$28.8M
Net Profit
$3.3M
$282.0K
Gross Margin
41.2%
83.6%
Operating Margin
18.6%
-32.8%
Net Margin
7.0%
1.0%
Revenue YoY
13.8%
Net Profit YoY
-33.3%
100.5%
EPS (diluted)
$0.13
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCL
CMCL
XFOR
XFOR
Q1 25
$28.8M
Q3 24
$46.9M
Q2 24
$50.1M
Q1 24
$38.5M
$0
Q4 23
$38.7M
Q3 23
$41.2M
$0
Q2 23
$37.0M
$0
Q1 23
$29.4M
Net Profit
CMCL
CMCL
XFOR
XFOR
Q1 25
$282.0K
Q3 24
$3.3M
Q2 24
$10.2M
Q1 24
$2.1M
$-51.8M
Q4 23
$-2.6M
Q3 23
$4.9M
$-2.3M
Q2 23
$-2.5M
$-55.7M
Q1 23
$-4.6M
Gross Margin
CMCL
CMCL
XFOR
XFOR
Q1 25
83.6%
Q3 24
41.2%
Q2 24
45.8%
Q1 24
35.9%
Q4 23
27.3%
Q3 23
34.3%
Q2 23
29.5%
Q1 23
19.9%
Operating Margin
CMCL
CMCL
XFOR
XFOR
Q1 25
-32.8%
Q3 24
18.6%
Q2 24
32.2%
Q1 24
13.8%
Q4 23
6.0%
Q3 23
22.4%
Q2 23
2.5%
Q1 23
-5.1%
Net Margin
CMCL
CMCL
XFOR
XFOR
Q1 25
1.0%
Q3 24
7.0%
Q2 24
20.3%
Q1 24
5.4%
Q4 23
-6.7%
Q3 23
12.0%
Q2 23
-6.8%
Q1 23
-15.8%
EPS (diluted)
CMCL
CMCL
XFOR
XFOR
Q1 25
$0.04
Q3 24
$0.13
Q2 24
$0.42
Q1 24
$0.07
$-7.77
Q4 23
$-0.19
Q3 23
$0.21
$-0.01
Q2 23
$-0.14
$-0.33
Q1 23
$-0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCL
CMCL
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$7.2M
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$231.0M
$22.9M
Total Assets
$339.7M
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCL
CMCL
XFOR
XFOR
Q1 25
$40.3M
Q3 24
$7.2M
Q2 24
$15.4M
Q1 24
$1.8M
$60.5M
Q4 23
$6.7M
Q3 23
$10.8M
$131.6M
Q2 23
$12.8M
$136.4M
Q1 23
$19.0M
Total Debt
CMCL
CMCL
XFOR
XFOR
Q1 25
$75.0M
Q3 24
Q2 24
Q1 24
$55.0M
Q4 23
Q3 23
$55.0M
Q2 23
$32.5M
Q1 23
Stockholders' Equity
CMCL
CMCL
XFOR
XFOR
Q1 25
$22.9M
Q3 24
$231.0M
Q2 24
$231.1M
Q1 24
$220.3M
$1.0M
Q4 23
$224.2M
Q3 23
$226.6M
$67.6M
Q2 23
$224.3M
$67.5M
Q1 23
$223.4M
Total Assets
CMCL
CMCL
XFOR
XFOR
Q1 25
$130.0M
Q3 24
$339.7M
Q2 24
$338.5M
Q1 24
$321.8M
$112.2M
Q4 23
$328.3M
Q3 23
$320.3M
$173.3M
Q2 23
$313.9M
$173.4M
Q1 23
$320.0M
Debt / Equity
CMCL
CMCL
XFOR
XFOR
Q1 25
3.27×
Q3 24
Q2 24
Q1 24
53.09×
Q4 23
Q3 23
0.81×
Q2 23
0.48×
Q1 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCL
CMCL
XFOR
XFOR
Operating Cash FlowLast quarter
$4.6M
$-12.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.40×
-43.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCL
CMCL
XFOR
XFOR
Q1 25
$-12.4M
Q3 24
$4.6M
Q2 24
$19.1M
Q1 24
$-33.6M
Q4 23
Q3 23
$14.5M
$-68.8M
Q2 23
$-2.2M
$-47.9M
Q1 23
Free Cash Flow
CMCL
CMCL
XFOR
XFOR
Q1 25
Q3 24
Q2 24
Q1 24
$-33.7M
Q4 23
Q3 23
$-68.8M
Q2 23
$-47.9M
Q1 23
Capex Intensity
CMCL
CMCL
XFOR
XFOR
Q1 25
0.0%
Q3 24
Q2 24
Q1 24
Q4 23
Q3 23
Q2 23
Q1 23
Cash Conversion
CMCL
CMCL
XFOR
XFOR
Q1 25
-43.86×
Q3 24
1.40×
Q2 24
1.87×
Q1 24
Q4 23
Q3 23
2.94×
Q2 23
Q1 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons